EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program

Andres J Yarur, Michael V Chiorean, Jessica R Allegretti iD, Raymond K Cross, Christina Ha iD, Martina Goetsch, Aoibhinn McDonnell, Alexis B Dalam, Joseph Wu, David A Blanco, Arcangelo M Abbatemarco iD, Julian Panés

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae288 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Andres J Yarur und 11 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Institute and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). We assessed the benefit of etrasimod monotherapy and the impact of concomitant corticosteroids (CS) and/or 5-aminosalicylates (5-ASA) therapy.

Methods

In ELEVATE UC 52 and ELEVATE UC 12, patients with moderately to severely active UC were randomized 2:1 to etrasimod 2 mg QD or placebo for 52 and 12 weeks, respectively. Oral CS or 5-ASA were allowed at baseline. Patients in the monotherapy subgroup received etrasimod or placebo without concomitant CS and/or 5-ASA at baseline. Predefined primary (clinical remission) and key secondary efficacy endpoints aligned with those from both trials and were assessed at Week 12 and Week 52. Safety was assessed up to Week 52.

Results

Clinical remission rates at Weeks 12 and 52 were significantly higher for etrasimod compared with placebo in patients receiving monotherapy (Week 12: 26.2% vs 4.8%; Week 52: 35.7% vs 4.0%). Differences vs placebo were statistically significant for all predefined endpoints at both time points in patients receiving monotherapy or etrasimod with concomitant 5-ASA only (all P < .05); numerical differences, due to small sample sizes, vs placebo were observed for all endpoints in the CS only and CS + 5-ASA subgroups. Safety was consistent with the overall population.

Conclusions

Etrasimod monotherapy showed consistent efficacy and safety vs placebo; no apparent benefit was observed with concomitant CS and/or 5-ASA in patients receiving etrasimod. Clinical trial registration NCT03945188; NCT03996369.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMesalamineAdrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleMiddle AgedAdultDrug Therapy, CombinationDouble-Blind MethodTreatment OutcomeFollow-Up StudiesAgedRemission InductionPrognosisYoung Adult

Stichwörter der Autor:innen

45 receptor modulator5-ASAcorticosteroidetrasimodsphingosine 1-phosphate1ulcerative colitis

Substanzen

MesalamineAdrenal Cortex HormonesAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Institute and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Inflammatory Bowel Disease Center, Swedish Medical Center, Seattle, WA, USA.
  • Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Gastroenterology and Hepatology, Melissa L. Posner Institute for Digestive Health and Liver Diseases at Mercy Medical Center, Baltimore, MD, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
  • Pfizer AG, Zürich, Switzerland.

ORCID-Profile: Jessica R Allegretti, Christina Ha, Arcangelo M Abbatemarco

Förderung

  • Pfizer

Zitieren

APA

Yarur, A. J., Chiorean, M. V., Allegretti, J. R., Cross, R. K., Ha, C., Goetsch, M., McDonnell, A., Dalam, A. B., Wu, J., Blanco, D. A., Abbatemarco, A. M., & Panés, J. (2025). Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae288

Vancouver

Yarur AJ, Chiorean MV, Allegretti JR, Cross RK, Ha C, Goetsch M, et al. Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae288

BibTeX
@article{Yarur2025,
  author = {Yarur, Andres J and Chiorean, Michael V and Allegretti, Jessica R and Cross, Raymond K and Ha, Christina and Goetsch, Martina and McDonnell, Aoibhinn and Dalam, Alexis B and Wu, Joseph and Blanco, David A and Abbatemarco, Arcangelo M and Panés, Julian},
  title = {Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae288}
}
Kostenlos starten →